NVDA−4.40%AAPL+1.23%GOOGL−3.15%MSFT−2.23%AMZN−4.57%TSM−4.52%SPCX−9.14%META−6.98%
StockVS

NASDAQ · Diagnostics & Research · USD

Freenome, Inc. (FRNM) Stock Analysis

Freenome, Inc. (FRNM) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 22, 2026

FRNM

$13.10

−$0.91 (−6.50%)

Oct 22, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FRNM with… →

FRNM Key Statistics

As of Oct 22, 2026
Trading
Open
$13.88
Previous Close
$14.01
Day's Range
12.69–13.93
52-Week Range
9.95–17.50
Volume
586.70K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.45
Valuation
Market Cap
$1.41B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
39.75
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.04
Financials (FY)
Revenue (FY)
$30.41M+955.14%
Net Income (FY)
−$219.34M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
107.45M
1-Year Return
+22.66%
Dividend and dates
Avg Volume
870.28K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 22, 2026, FRNM closed at $13.10, +22.66% over 1 year.

Freenome, Inc. (FRNM) has a market capitalization of $1.41B.

In fiscal 2025, FRNM reported revenue of $30.41M.

FRNM Stock Return by Calendar Year

Freenome, Inc. (FRNM) return since Jun 2024: what $10,000 became

1 year
$10,000 $12,266
+22.66%
Since Jun 2024
$10,000 $13,035
+30.35%

If you had invested $10,000 in Freenome, Inc. (FRNM) at the close on June 12, 2024, the earliest close on record here, it would have been worth $13,035 at the close on October 22, 2026: +30.35% in total, +11.89% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+0.54%
2025+28.00%
2024 (partial year)+1.29%

As of October 22, 2026.

FRNM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$30.41M−$219.34M−721.3%
2024$2.88M−$274.42M−9,521.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$30.41M$28.47M−$223.47M−$219.34M−721.3%
2024$2.88M$318.00K−$291.97M−$274.42M−9,521.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

FRNM Valuation vs Diagnostics & Research Median

Median of 45 stocks
MetricFRNMDiagnostics & Research medianvs median
P/S ratio39.755.117.8x the median

Medians across 45 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 22, 2026.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Freenome, Inc. (FRNM) at $1.41B. The company sits in the Healthcare sector, in the Diagnostics & Research industry. The company reports 375 employees.

FRNM last closed at $13.10 on October 22, 2026. That is −$0.91 (−6.50%) against the previous close. The 52-week range on file runs from $9.95 to $17.50. The latest close sits 31.66% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $30.41M. That is +955.14% against the prior fiscal year, when revenue was $2.88M. The same year closed with a net loss of $219.34M. Trailing earnings per share are −2.04.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 39.75 times revenue. On price-to-sales that is 7.8 times the Diagnostics & Research median of 5.11. 45 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is +22.66%. The stored price history starts on June 12, 2024, and the total return since then is +30.35%. The reported beta is 0.45. Annualized volatility over the trailing 2 years is 34.94%.

Growth & Income

No dividend is on file for FRNM.

So far in 2026 the total return is +0.54%. The record holds one complete calendar year, 2025, which returned +28.00%.

Peer Comparison

Freenome, Inc. (FRNM) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Freenome, Inc. FRNM $1.41B —
Thermo Fisher Scientific Inc. TMO $250.15B 35.7
Danaher Corporation DHR $161.51B 38.0
Natera, Inc. NTRA $57.86B —

The Diagnostics & Research industry average P/E ratio is 36.0x. Freenome, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 22, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$250.15B

 DHR

Danaher Corporation

$161.51B

 NTRA

Natera, Inc.

$57.86B

 A

Agilent Technologies, Inc.

$49.03B

 IQV

IQVIA Holdings Inc.

$45.81B

 WAT

Waters Corporation

$44.73B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.17T

 JNJ

Johnson & Johnson

$644.91B

 ABBV

AbbVie Inc.

$503.96B

 UNH

UnitedHealth Group Incorporated

$381.46B

 MRK

Merck & Co., Inc.

$363.27B
View all Healthcare stocks →

About Freenome, Inc.

Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen™ CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.

Visit website →